Biofeedback for Hemianopia Vision Rehabilitation
Patients with brain injury secondary to stroke, surgery, or trauma frequently suffer from homonymous hemianopia, defined as vision loss in one hemifield secondary to retro- chiasmal lesion. Classic and effective saccadic compensatory training therapies are current aim to reorganize the control of visual information pro
| Condition(s) | Hemianopsia, Homonymous, Brain Injury, Stroke, Brain Tumor, Brain Trauma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Patients with brain injury secondary to stroke, surgery, or trauma frequently suffer from homonymous hemianopia, defined as vision loss in one hemifield secondary to retro- chiasmal lesion. Classic and effective saccadic compensatory training therapies are current aim to reorganize the control of visual information processing and eye movements or, in other words, to induce or improve oculomotor adaptation to visual field loss. Patients learn to intentionally shift their eyes and, thus, their visual field border, into the area corresponding to their blind visual field. This shift brings the visual information from the blind hemifield into the seeing hemifield for further processing. Patients learn, therefore, to efficiently use their eyes "to keep the 'blind side' in sight". Biofeedback tra |
| Who can participate | Inclusion Criteria: * hemianopia cases previously diagnosed accordingly by microperimetry and other tests as needed * 18-90 years old * ability to follow the visual and auditory stimuli and training instructions Exclusion Criteria: * previous or current treatment for low vision rehabilitation * ocular diseases * other serious clinical conditions not related to the hemianopia physiopathology * both eyes with media opacity that impairs microperimetry testing * lack of ability to perform the tests and training |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Lead sponsor | University Health Network, Toronto |
| Locations | Toronto, Ontario, Canada |
| Start date | 2021-12-01 |
| NCT ID | NCT05397873 |
| Official listing | https://clinicaltrials.gov/study/NCT05397873 |